THE NEW YORK TIMES EXPOSE OF ELI LILLY SECRET ZYPREXA DOCUMENTS Part II.
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
AHRP Testimony presented by Vera Sharav, December 2006. PowerPoint slides (843 kb file).
Two ground breaking legal actions in Texas to rein in out of control psychotropic drug prescribing will have nationwide reverberations.
The Alliance for Human Research Protection joins the effort of Union of Concerned Scientists to stop Stephen Johnson and the U.S. Evironmental Protection Agency from engaging in irresponsible conduct–much like marauders–who have embarked on destroying valuable data! This is tantamount to Book . . . Continue reading →
BBC reports that "Up to one in three mental health patients are being over-prescribed drugs, says the Healthcare Commission."
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
Two Press Briefings are planned to demonstrate the multiple flaws in FDA's methodology and to provide credible science-based information.
"the first-ever randomized, placebo-controlled trial for the alleviation of post-traumatic stress disorder (PTSD)" reports: "we found that it really offered patients no benefits of any symptoms."  Continue reading →
Australian psychiatrist: "Does anyone else see tardive dysmentia after atypicalantipsychotics?"
U.S. Doctors are prescribing the antidepressant, Effexor (150mg) for infants under age one!
Unssuccessful effort to engage debate within the community of the authorized clinical research gatekeepers charged with protecting the safety and welfare of the human subjects of research–i.e., members of institutional review boards (IRBs–REBs in Canada). Continue reading →